A recent Twitter conversation between a blogging colleague of mine and a German advocate of precision medicine propelled this post: What is the real benefit of biosimilars? Does biosimilar development detract from efforts to produce innovative medicines? Is the main societal benefit biosimilar cost savings? Biosimilar Development Is Separate From Innovation Development The main reason … Continue reading Let’s not Knock Innovation, but Biosimilars Exist for the Sake of Competition →